Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
Trial details
- Registry ID
- NCT06617429
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as apazunersen
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)NCT06617429 | RARE | Phase 3 | Terminated | 2026-07-10Actual |
| A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)NCT07157254 | RARE | Phase 2 | Terminated | 2026-10-30Actual |
| Long-term Extension of GTX-102 in Angelman SyndromeNCT06415344 | RARE | Phase 3 | Terminated | 2026-10-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |